AU2001267823A1 - Compounds exhibiting x-type spla2 inhibiting effect - Google Patents
Compounds exhibiting x-type spla2 inhibiting effectInfo
- Publication number
- AU2001267823A1 AU2001267823A1 AU2001267823A AU6782301A AU2001267823A1 AU 2001267823 A1 AU2001267823 A1 AU 2001267823A1 AU 2001267823 A AU2001267823 A AU 2001267823A AU 6782301 A AU6782301 A AU 6782301A AU 2001267823 A1 AU2001267823 A1 AU 2001267823A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibiting effect
- compounds exhibiting
- type spla2
- spla2
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-195430 | 2000-06-29 | ||
JP2000195430 | 2000-06-29 | ||
PCT/JP2001/005479 WO2002000621A1 (en) | 2000-06-29 | 2001-06-27 | Compounds exhibiting x-type spla2 inhibiting effect |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001267823A1 true AU2001267823A1 (en) | 2002-01-08 |
Family
ID=18694092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001267823A Abandoned AU2001267823A1 (en) | 2000-06-29 | 2001-06-27 | Compounds exhibiting x-type spla2 inhibiting effect |
Country Status (4)
Country | Link |
---|---|
US (3) | US7026318B2 (en) |
JP (1) | JPWO2002000621A1 (en) |
AU (1) | AU2001267823A1 (en) |
WO (1) | WO2002000621A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI314457B (en) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
US6900208B2 (en) * | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
NZ541232A (en) * | 2003-01-09 | 2008-02-29 | Astellas Pharma Inc | Pyrrolopyridazine derivatives |
US7030112B2 (en) * | 2003-03-25 | 2006-04-18 | Bristol-Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
AU2005209115A1 (en) * | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
US8097623B2 (en) * | 2005-01-19 | 2012-01-17 | Biolipox Ab | Indoles useful in the treatment of inflammation |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
JP5205971B2 (en) * | 2006-01-27 | 2013-06-05 | 宇部興産株式会社 | Method for producing tetrahydropyran compound |
US8048880B2 (en) * | 2007-05-03 | 2011-11-01 | Anthera Pharmaceuticals, Inc. | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies |
JP5791500B2 (en) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ,エルエルシー. | 5-lipoxygenase activating protein inhibitor |
DE202009003977U1 (en) | 2009-03-24 | 2009-07-30 | Horst E. Otten Matratzenfabrik Gmbh | Adjustment mechanism, especially for slatted frames and beds |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
WO2012154967A1 (en) * | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
US10894035B2 (en) * | 2015-08-31 | 2021-01-19 | Diaccurate | Use of indole compounds to stimulate the immune system |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
US5981252A (en) * | 1993-06-25 | 1999-11-09 | Smithkline Beecham | Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
US5498608A (en) * | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
MY112897A (en) * | 1994-04-01 | 2001-10-31 | Lilly Co Eli | Ih-indole-3-glyoxylamide spla2 inhibitors |
US6214876B1 (en) * | 1994-07-21 | 2001-04-10 | Eli Lilly And Company | Indene-1-acetamide sPLA2 inhibitors |
US5641800A (en) | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
US6645976B1 (en) * | 1994-07-21 | 2003-11-11 | Eli Lilly And Company | Indolizine SPLA2inhibitors |
BR9612347A (en) | 1995-12-13 | 1999-07-13 | Lilly Co Eli | Naphthyl acetamides as spla2 inhibitors |
HUP9902120A3 (en) | 1995-12-13 | 1999-12-28 | Lilly Co Eli | Naphthyl glyoxamides as spla2 inhibitors |
CZ136899A3 (en) | 1996-10-30 | 1999-09-15 | Eli Lilly And Company | Substituted tricyclic compounds |
US6353128B1 (en) | 1996-12-03 | 2002-03-05 | Eli Lilly And Company | Phenyl acetamides as sPLA2 inhibitors |
US5916922A (en) | 1996-12-03 | 1999-06-29 | Eli Lilly And Company | Phenyl glyoxamides as SPLA2 inhibitors |
ID18983A (en) | 1996-12-04 | 1998-05-28 | Lilly Co Eli | PIRAZOLA AS AN NON-PANCREAS PHOSPHOLIPASE SECRETARY SECRESSION IN HUMAN |
US5919774A (en) | 1996-12-10 | 1999-07-06 | Eli Lilly And Company | Pyrroles as sPLA2 inhibitors |
AU6229298A (en) | 1997-02-20 | 1998-09-09 | Shionogi & Co., Ltd. | Indole dicarboxylic acid derivatives |
US6610728B2 (en) | 1997-08-28 | 2003-08-26 | Eli Lilly And Company | Method for treatment of non-rheumatoid arthritis |
EP1007056A1 (en) | 1997-09-26 | 2000-06-14 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
EP1039901A1 (en) | 1997-11-14 | 2000-10-04 | Eli Lilly And Company | Treatment for alzheimer's disease |
CN1303384A (en) | 1998-03-31 | 2001-07-11 | 盐野义制药株式会社 | Pyrrolo [1,2-a] pyrazine sPLA2 inhibitor |
HUP0102243A2 (en) | 1998-05-01 | 2001-10-28 | Eli Lilly And Co. | Spla2 inhibitor compounds for treatment of disease |
US6472389B1 (en) * | 1998-05-21 | 2002-10-29 | Shionogi & Co., Ltd. | Pyrrolo[1,2-b] pyridazine derivatives having sPLA2 inhibitory effect |
US6384041B1 (en) * | 1998-06-30 | 2002-05-07 | Eli Lilly And Company | Bicyclic sPLA2 inhibitors |
CA2346334A1 (en) * | 1998-10-14 | 2000-04-20 | Shionogi & Co., Ltd. | Composition for treating or preventing ischemia reperfusion injury |
AU7559600A (en) | 1999-10-15 | 2001-04-23 | Shionogi & Co., Ltd. | V type and/or x type spla2 inhibitors |
TWI314457B (en) * | 2001-03-19 | 2009-09-11 | Shionogi & Co |
-
2001
- 2001-06-27 AU AU2001267823A patent/AU2001267823A1/en not_active Abandoned
- 2001-06-27 WO PCT/JP2001/005479 patent/WO2002000621A1/en active Application Filing
- 2001-06-27 JP JP2002505369A patent/JPWO2002000621A1/en active Pending
- 2001-06-27 US US10/311,282 patent/US7026318B2/en not_active Expired - Fee Related
-
2005
- 2005-11-16 US US11/274,308 patent/US20060116379A1/en not_active Abandoned
-
2009
- 2009-07-24 US US12/458,846 patent/US20090286796A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JPWO2002000621A1 (en) | 2004-04-22 |
US7026318B2 (en) | 2006-04-11 |
US20090286796A1 (en) | 2009-11-19 |
WO2002000621A1 (en) | 2002-01-03 |
US20030181454A1 (en) | 2003-09-25 |
US20060116379A1 (en) | 2006-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001241128A1 (en) | Novel amide compounds | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2002225730A1 (en) | Compounds | |
AU2001274009A1 (en) | Substituted indoles as parp inhibitors | |
AU4878601A (en) | Aromatic amide compounds | |
AU2002218266A1 (en) | Novel indanylidene compounds | |
AU2001286243A1 (en) | Tetrahydroquinoline compounds | |
AU2001292518A1 (en) | Novel compounds | |
AU2001267823A1 (en) | Compounds exhibiting x-type spla2 inhibiting effect | |
AU4430701A (en) | Compounds for targeting | |
AUPQ661800A0 (en) | Insulin-potentiating compounds | |
AU2001239765A1 (en) | Novel compounds | |
AU2001246998A1 (en) | Novel compounds | |
AU2001230605A1 (en) | Apoptosis inhibitor | |
AU2001253362A1 (en) | Novel compounds | |
AU2001244562A1 (en) | Neovascularization inhibitors | |
AU3997700A (en) | Anti-first-pass effect compounds | |
AU2002231077A1 (en) | Novel compounds | |
AU2001260661A1 (en) | Compounds exhibiting thrombopoietin-like activities | |
AU2001278086A1 (en) | Pseudo addressing | |
AU2001256964A1 (en) | Novel compounds | |
AU2002225724A1 (en) | Motilide compounds | |
AU2002217285A1 (en) | Compounds | |
AU2001230689A1 (en) | Novel compounds | |
AU2001280461A1 (en) | Substituted pyrrole compounds and their use as spla2 inhibitors |